Study guide

13.4 Stimulant Harm Reduction, Overamping & Patient Education

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

13.4 Stimulant Harm Reduction, Overamping & Patient Education

Key Takeaways Explain This Topic AI

Fentanyl contaminates a large share of the illicit stimulant supply, so every person who uses stimulants should be offered naloxone and taught overdose recognition even if they never intentionally use opioids.

Overamping describes overwhelming stimulant intoxication with agitation, chest pain, hyperthermia or psychosis; unlike opioid overdose it has no antidote, and naloxone will not reverse it.

Safer-smoking supplies reduce the wound and infection burden of pipe sharing and reduce transitions from smoking to injection.

Sexualized stimulant use, sometimes called chemsex or party and play, markedly increases HIV, hepatitis C and syphilis transmission risk and should trigger PrEP discussion and routine testing.

Hydration, cooling, rest, dental care and eating are the highest-yield self-care messages for people who continue to use stimulants.

Last updated: September 2026

13.4 Stimulant Harm Reduction, Overamping & Patient Education

Quick Answer: People who use stimulants now die overwhelmingly from opioid-contaminated supply , so naloxone, fentanyl test strips, and never-use-alone strategies apply to every stimulant patient . Overamping — overwhelming stimulant intoxication with agitation, chest pain, hyperthermia, or psychosis — has no antidote ; management is cooling, calm environment, hydration and emergency care for chest pain, severe hyperthermia or altered mental status. Core teaching also covers safer smoking supplies , sexual health and PrEP , hydration and cooling , sleep , eating , and dental care .

1. The Contaminated Supply Problem

Illicitly manufactured fentanyl is present in a substantial and rising share of counterfeit pills and powder stimulants, and some people who use stimulants are opioid-naive with no tolerance whatsoever . This produces a specific, teachable risk profile:

Every stimulant patient is offered naloxone. The most common objection — "I don't do opioids" — is precisely the reason the risk is high: no tolerance means a small fentanyl exposure can be fatal.

Fentanyl test strips detect fentanyl and many analogues in a dissolved sample. Teach the correct method: dissolve a small residue in water, dip the strip, read at the specified time, and understand that a negative result does not guarantee safety because of uneven distribution in a batch (the "chocolate chip cookie" problem).

Never use alone. Options include using with someone who has naloxone and is not using at the same time, a national overdose prevention hotline, or an overdose prevention center where legally available.

Teach the difference between overamping and opioid overdose. Opioid overdose produces unresponsiveness, slow or absent breathing, and pinpoint pupils ; overamping produces agitation, hyperthermia, chest pain, or psychosis with normal or fast breathing . If it is not clear which is occurring and the person is unresponsive with poor breathing, give naloxone — it is harmless if the cause is stimulant only.

2. Overamping

Domain Manifestation What to teach

Physical Chest pain, palpitations, severe headache, overheating, muscle rigidity, seizures Chest pain, worst-ever headache, temperature that will not come down, or seizure means call emergency services

Psychological Panic, paranoia, terrifying hallucinations, suicidal thoughts Move to a quiet, dim, cool space with a trusted person; reduce stimulation; do not argue with delusional content

Self-management Overheating and dehydration Cool water on skin, cool fluids in sips, remove excess clothing, stop using more, rest

What does not work Naloxone, "sleeping it off" alone, more stimulant to "push through" Explicitly correct the belief that naloxone reverses stimulant toxicity

3. Route-Specific Harm Reduction

Smoking. Provide unshared pipes and mouthpieces. Shared pipes transmit hepatitis C and cause burns and oral lesions; heat-cracked glass lacerates lips and gums. Access to safer smoking supplies is also associated with fewer transitions from smoking to injection , which is the single most consequential route change for infection risk.

Injection. Sterile syringes, cookers, cotton and water; single use of each; rotation of sites; skin preparation with alcohol before injection. Teach recognition of cellulitis, abscess and endocarditis, and that a new murmur with fever is an emergency.

Intranasal. Do not share straws or bills — hepatitis C transmission through shared snorting equipment is plausible and mucosal damage is common. Saline rinses reduce septal injury.

Dental. Stimulant users have very high rates of rampant caries driven by xerostomia, bruxism, sugary drinks and neglected hygiene. Sugar-free gum, fluoride rinse, water, and a realistic dental referral pathway are concrete, high-yield teaching.

4. Sexual Health

Sexualized stimulant use — often called chemsex or party and play — is associated with prolonged sexual sessions, multiple partners, condomless anal sex, and markedly increased transmission of HIV, hepatitis C, syphilis and gonorrhea . APRN actions:

Ask about sexualized use directly and without judgment; it changes the risk assessment completely.

Offer HIV pre-exposure prophylaxis and discuss which agent fits the patient's exposure profile.

Provide condoms and lubricant, and test for HIV, hepatitis C and syphilis at intervals matched to ongoing risk rather than annually by default.

Discuss doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections where locally recommended.

5. The Five-Minute Teaching Script

Because Educate carries 25% of CARN-AP items , it is worth having a compact, repeatable script:

Naloxone. "Even if you never use opioids, the supply is contaminated. Here are two doses and here is how to use them."

Not alone. "If you use alone, use the hotline or have someone check on you."

Heat and water. "Overheating is what hurts people. Cool water, shade, and stop when your chest hurts or your head is pounding."

Sleep and food. "After a run, the crash is chemical. Sleep is treatment. Eat before you crash, not after."

One thing you will do. End by asking the patient to name one change they will actually make, and use teach-back to confirm the plan in their own words.